Drug
Dibotermin alfa clinical trials
Also written InductOs and RhBMP-2.
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2003 (2)
| Year | Studies |
|---|---|
| 2003 | 2 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2011 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 3
Wyeth is now a wholly owned subsidiary of Pfizer (6) · University of Zurich (1) · Xijing Hospital (1) · University of Baghdad (1)
Studies
Open first, then newest update. How each study uses dibotermin alfa is read from its arms, and is right about nine times in ten.
Testing it · 9
- Recombinant Human Bone Morphogenetic Protein-2(rhBMP-2) in Patients With Osteoporosis After Lumbar FusionStatus unknownNot applicableXijing HospitalNCT05911477Written as RhBMP-2
- Effect of Recombinant Human Bone Morphogenetic Protein-2 With an Absorbable Collagen Sponge on Stability of Dental Implant: (Split Mouth Randomized Clinical Trial Study.Status unknownPhase 1University of BaghdadNCT05719181Written as rhBMP-2
- Lateral Ridge Augmentation Using Autogenous Bone Blocks or Xenogenic Bone Block Grafts Loaded With Recombinant Human Bone Morphogenic Protein 2CompletedPhase 3University of ZurichNCT01541345Written as InductOs
- Feasibility And Safety Study Of rhBMP-2/CPM For Hip FracturesCompletedPhase 2Wyeth is now a wholly owned subsidiary of PfizerNCT00384358Written as rhBMP-2/CPM
- A Study of rhBMP-2/CPM in Closed Fractures of the HumerusCompletedPhase 2Wyeth is now a wholly owned subsidiary of PfizerNCT00384852Written as rhBMP-2/CPM
- A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial FracturesTerminatedPhase 2/3Wyeth is now a wholly owned subsidiary of PfizerNCT00387686Written as rhBMP-2/CPM
- Study Evaluating InductOs in Diaphyseal Tibia FracturesCompletedPhase 4Wyeth is now a wholly owned subsidiary of PfizerNCT00161616Written as InductOs
- Study Evaluating rhBMP-2/CPM in Closed Distal Radius FracturesCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00161629Written as rhBMP-2/CPM
- Study Evaluating rhMBP-2/CPM in Open Wedge OsteotomiesCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00243295Written as rhBMP-2/CPM
Codes
What other systems call dibotermin alfa · ClinicalTrials.gg INT017970
- UNII (FDA) T472P45MG6DIBOTERMIN ALFAConfirmed FDA, Wikidata
- Wikidata Q28852431dibotermin alfaConfirmed FDA, Wikidata
- NCI Thesaurus C132249Dibotermin AlfaOne source FDA
- DrugBank DB11639One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | T472P45MG6 | DIBOTERMIN ALFA | Confirmed FDA, Wikidata |
| Wikidata | Q28852431 | dibotermin alfa | Confirmed FDA, Wikidata |
| NCI Thesaurus | C132249 | Dibotermin Alfa | One source FDA |
| DrugBank | DB11639 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.